| Today's Big NewsJan 6, 2023 |
|
The National Biotechnology and Biomanufacturing Initiative, which channels more than $2 billion to America’s biotech sector, will have far-reaching implications not only for the domestic biotech space but industries at large, including life sciences. Where are the salient opportunities? What are the gravest risks? Read this in-depth white paper from Randstad for answers. 
|
|
| By Nick Paul Taylor Pfizer is stepping back from early-stage rare disease R&D. After reviewing its portfolio, the Big Pharma has begun “exploring externalization opportunities for a number of highly innovative, niche programs” as part of a rethink of its approach to orphan indications. |
|
|
|
By Annalee Armstrong CureVac and GSK have picked two mRNA candidates for flu and COVID-19 after seeing phase 1 data. While analysts were happy to see the win, they were skeptical of the lack of updated variant data and limited population read-out—even going so far as to call the disclosure “half-baked.” |
By James Waldron Moderna clearly has no interest in taking a pre-JPM breather. In the week ahead of the conference, the mRNA giant has already announced its first-ever acquisition, organized a CEO interview with Fierce Biotech—and now signed a protein-focused partnership to better target its therapies. |
By Nick Paul Taylor Fate Therapeutics has begun 2023 with a big reset of its business. Having ended its collaboration with Johnson & Johnson, the cell therapy biotech has decided to slash its head count and stop multiple clinical development programs to stretch out its cash runway. |
|
Download this whitepaper for guidance on how to Scale your Direct-to-Consumer Microbiome Testing Company and when it makes sense to outsource microbiome sequencing to a third-party provider. 
|
|
By Gabrielle Masson AbbVie is doling out $30 million in cash to ink an oncology pact with Immunome and potentially identify up to 10 new target-antibody pairs using the biotech’s discovery engine. |
By James Waldron A year and a half after exceeding expectations with its $238 million IPO, Graphite has hit a major roadblock as an adverse event caused the gene-therapy-focused biotech to pause its lead program. |
By James Waldron If last year was marred by continual stories of biotechs laying off staff and pruning back their pipelines to survive, then this week’s news suggests the new year hasn’t quite brought the fresh start the industry was hoping for. |
By Angus Liu While Novo Nordisk, AstraZeneca and Eli Lilly are set to lead their pharma peers with the most top-line growth this year, Merck & Co. and Sanofi are notably absent from the projection despite major expected contributions from their star meds, a new Evaluate report shows. |
By Ben Adams Less than a week into 2023, and we already have a biotech name change as PsiOxus Therapeutics becomes Akamis Bio. |
By Conor Hale The Mount Sinai spinout raised $16 million to continue developing its test that looks for environmental exposures trapped within a piece of hair. |
By Kevin Dunleavy With a pediatric approval in June for its next-generation pneumococcal vaccine, Merck leads a high-stakes race with Pfizer to capture the competition’s key demographic. But Pfizer is quickly gaining ground with its next-gen shot that offers more protection. Friday, the FDA designated Prevnar 20 for priority review in children aged 6 weeks through 17 years. |
By Gabrielle Masson,Max Bayer Gilead-backed Galapagos went through a 2022 pipeline pivot without a chief scientific officer, and now it starts 2023 down two additional C-suite members. |
By Angus Liu Eisai is facing more lecanemab patient deaths in its Alzheimer's disease trial ahead of expected FDA decision. Moderna struck its first acquisition. GSK has bet up to $1.5 billion on WuXi Biologics' CD3 T-cell engagers. And more. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now. 
|
|
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
